At Gilead we are inspired by the opportunity to address unmet medical needs for patients living with life-threatening diseases around the world.
With each new discovery and investigational drug candidate, we seek to improve care for people living with HIV/AIDS, liver diseases, cardiovascular and respiratory conditions, cancer and inflammation.
We are a culture that shares one common focus - advancing the discovery, development and delivery of new medications for people worldwide.
Gilead plays a central role in developing single tablet regimens – with one pill once a day, patients can take all of their medication in each dose.
Our liver disease programs focus on expanding treatment options for chronic hepatitis B and C.
Our medicines aim to help patients with cardiovascular disease return to their daily activities, and we are exploring potential new indications such as diabetes.
We research and develop treatments for serious respiratory conditions such as influenza, cystic fibrosis and other diseases of the lungs.
Our scientists are applying new knowledge about how cancers grow and spread to potentially enhance and improve cancer therapy.
Gilead medicines treat severe fungal and parasitic infections, and address vision loss caused by degenerative eye diseases.
Gilead makes it a priority to ensure that people who need our therapies have access, regardless of their ability to pay or where they live in the world.
December 07, 2013
Gilead Announces Interim Phase 2 Results for GS-9973 in Previously Treated Chronic Lymphocytic Leukemia